Transplant patients with skin cancer get new hope from engineered virus
NCT ID NCT04349436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. Participants receive injections every two weeks for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP1 (a genetically modified herpes simplex type 1 virus injected directly into tumors)
- What this could lead to
- If successful, this could offer a new treatment option for transplant patients with advanced skin cancers that are hard to treat.
- What could go wrong
- This is an early-phase trial with only 69 participants, so results may not apply to everyone. The virus could cause side effects or organ rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Medical Dermatology Specialists
Phoenix, Arizona, 85006, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Rochester Dermatologic Surgery
New York, New York, 14564, United States
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UCSF, Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94143, United States
-
University of California, Los Angeles
Los Angeles, California, 90024, United States
-
University of California, San Diego
La Jolla, California, 92093, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Colorado Cancer Center School of Medicine
Aurora, Colorado, 80045, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Tennessee Medical Center at Knoxville
Knoxville, Tennessee, 37920, United States
-
University of Texas Southwestern
Dallas, Texas, 75235, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?